Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]
Journal of Affective Disorders – January 05, 2024
Source: OpenAlex
Summary
Remarkable findings in clinical psychology show psilocybin, an alkaloid from chemical synthesis, significantly reduces depressive symptoms. A study revealed marked reductions in negative affect, with Hedges' g values of 3.1 at one week, 2.7 at five weeks, and 2.0 at three months. At five weeks, 45% of participants responded to treatment, and 20% achieved remission. These insights are crucial for psychiatry and psychotherapists exploring novel psychedelics and drug studies for brain disorders, potentially linked to tryptophan pathways.
Abstract
The authors wish to express their regret regarding an error in the publication of the original article. In Table 3, titled “Psilocybin studies on depressive disorders,” specifically in the fourth row related to the study conducted by Carhart-Harris et al. (2016), the main results column inaccurately presented the Cohen's d figure, which included data from Carhart-Harris et al. (2018) that pertained to eight additional participants, data which were not analyzed in Carhart-Harris et al. (2016). For the sake of clarity and accuracy, the corrected version should read as follows: 1-week: marked reduction in QIDS (Hedges' g = 3.1, p = .002) 5-week: marked reduction in QIDS (Hedges' g = 2.7, p = .003); response and remission rate at 45 % and 20 % 3-month: reduction in QIDS remained positive (Hedges' g = 2.0, p = .003). The authors would like to apologise for any inconvenience caused.